Target- |
MechanismIron preparation |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Austria |
First Approval Date21 Mar 2012 |
An open label trial evaluating the pharmacokinetics and safety of an intravenously administered single dose of Feramyl® 200 mg, 500 mg or 1500 mg vs. Ferinject® 500 mg in patients suffering from anaemia following cardiac surgery
An open label study on safety and pharmacokinetics of an intravenous administered single dose of Feramyl 200 mg in healthy blood donors compared to a single dose of Feramyl 1000 mg in IBD patients to evaluate dose dependency and kinetics after 1 hour infusion.
Open clinical study to determine the compatibility of Pyolysin®-Salbe in children aged between 0 and 17 years during the dermatological treatment of superficial wounds
100 Clinical Results associated with Serumwerk Bernburg AG
0 Patents (Medical) associated with Serumwerk Bernburg AG
100 Deals associated with Serumwerk Bernburg AG
100 Translational Medicine associated with Serumwerk Bernburg AG